Filtered By:
Condition: Heart Disease
Education: Learning
Procedure: Heart Transplant

This page shows you your search results in order of date.

Order by Relevance | Date

Total 32 results found since Jan 2013.

Cardiac disease prediction using AI algorithms with SelectKBest
AbstractAtherosclerotic cardiovascular disease (ASCVD), which includes coronary heart disease (CHD) and ischemic stroke, is the leading cause of mortality globally. According to the European Society of Cardiology (ESC), 26 million people worldwide have heart disease, with 3.6 million diagnosed each year. Early detection of heart disease will aid in lowering the mortality rate. The lack of diversity in training data and the difficulty in comprehending the findings of complicated AI models are the key issues in current research for heart disease prediction using artificial intelligence. To overcome this, in this paper, cardi...
Source: Medical and Biological Engineering and Computing - September 8, 2023 Category: Biomedical Engineering Source Type: research

Brain health and mental health: Common vascular risk factors and practical implications
Alzheimers Dement. 2023 May 22. doi: 10.1002/alz.13153. Online ahead of print.ABSTRACTThe pandemic dramatized the close links among cognitive, mental, and social health; a change in one reflects others. This realization offers the opportunity to bridge the artificial separation of brain and mental health, as brain disorders have behavioral consequences and behavioral disorders affect the brain. The leading causes of mortality and disability, namely stroke, heart disease, and dementia, share the same risk and protective factors. It is emerging that bipolar disorders, obsessive compulsive disorders, and some depressions shar...
Source: The Journal of Alzheimers Association - May 22, 2023 Category: Psychiatry Authors: Vladimir Hachinski Ennapadam Krishnamoorthy Levent Kuey Laurence J Kirmayer Source Type: research

Diagnosis of Coronary Artery Disease based on Machine Learning algorithms Support Vector Machine, Artificial Neural Network, and Random Forest
CONCLUSION: In this study, it was shown that machine learning algorithms can be used with high accuracy to detect CAD. Thus, it allows physicians to perform timely preventive treatment in patients with CAD.PMID:37057235 | PMC:PMC10086656 | DOI:10.4103/abr.abr_383_21
Source: Adv Data - April 14, 2023 Category: Epidemiology Authors: Saeed Saeedbakhsh Mohammad Sattari Maryam Mohammadi Jamshid Najafian Farzaneh Mohammadi Source Type: research

Straight from the heart: Mysterious lipids may predict cardiac problems better than cholesterol
Stephanie Blendermann, 65, had good reason to worry about heart disease. Three of her sisters died in their 40s or early 50s from heart attacks, and her father needed surgery to bypass clogged arteries. She also suffered from an autoimmune disorder that results in chronic inflammation and boosts the odds of developing cardiovascular illnesses. “I have an interesting medical chart,” says Blendermann, a real estate agent in Prior Lake, Minnesota. Yet Blendermann’s routine lab results weren’t alarming. At checkups, her low-density lipoprotein (LDL), or “bad,” cholesterol hovered around the 100 milligrams-per-...
Source: Science of Aging Knowledge Environment - March 16, 2023 Category: Geriatrics Source Type: research

New VOYAGER PAD Analysis Confirms Consistent Benefit of XARELTO ® (rivaroxaban) Plus Aspirin Following Lower Extremity Revascularization (LER)
TITUSVILLE, NJ, March 5, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from a new prespecified analysis from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefits of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) over standard of care (aspirin alone), demonstrating consistent benefit at 30 days, 90 days and up to three years following LER in patients with PAD. Lower extremity revascularization, also called peripheral revascularization, is a procedure that restores blood flow in blocked arteries or veins. This analysis of ...
Source: Johnson and Johnson - March 5, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Cardiovascular/Stroke Risk Assessment in Patients with Erectile Dysfunction-A Role of Carotid Wall Arterial Imaging and Plaque Tissue Characterization Using Artificial Intelligence Paradigm: A Narrative Review
Diagnostics (Basel). 2022 May 17;12(5):1249. doi: 10.3390/diagnostics12051249.ABSTRACTPURPOSE: The role of erectile dysfunction (ED) has recently shown an association with the risk of stroke and coronary heart disease (CHD) via the atherosclerotic pathway. Cardiovascular disease (CVD)/stroke risk has been widely understood with the help of carotid artery disease (CTAD), a surrogate biomarker for CHD. The proposed study emphasizes artificial intelligence-based frameworks such as machine learning (ML) and deep learning (DL) that can accurately predict the severity of CVD/stroke risk using carotid wall arterial imaging in ED ...
Source: Atherosclerosis - May 28, 2022 Category: Cardiology Authors: Narendra N Khanna Mahesh Maindarkar Ajit Saxena Puneet Ahluwalia Sudip Paul Saurabh K Srivastava Elisa Cuadrado-Godia Aditya Sharma Tomaz Omerzu Luca Saba Sophie Mavrogeni Monika Turk John R Laird George D Kitas Mostafa Fatemi Al Baha Barqawi Martin Miner Source Type: research

New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news